Animal Husbandry and Feed Science ›› 2016, Vol. 37 ›› Issue (3): 18-18.doi: 10.12160/j.issn.1672-5190.2016.03.006

Previous Articles     Next Articles

Effect of Kinetin on Immunity of Aging Model Mice

WU Ying-ying, LI Meng-yun, SONG Ge-ge, YAN Xiao-lan, ZHANG Ke-zhe, WANG Gang (Henan University of Science and Technology, Luoyang 471023, China)   

  • Online:2016-03-20 Published:2016-03-20

Abstract: In order to investigate the effect of kinetin on immunity of aging model mice, a total of 50 mice of Kunming strain were selected and divided into aging model control group, low dosage kinetin group, moderate dosage kinetin group, high dosage kinetin group, and young control group. There were 10 mice in each group with half males and half females. The mice in aging model control group and kinetin treatment groups were subcutaneously administrated 125 mg/(kg·BW)of D-galactose once daily on the back for consecutive 45 d. On day 11, the mice in low, moderate and high dosage kinetin group were intraperitoneally administrated with 5, 10, 20 mg/(kg·BW)of kinetin solutions once daily till 45th day; in the same period, the mice in aging model control group and young control group were subcutaneously administrated with saline on the back of the neck. At the end of the experiment, the spleen index of the mice in different groups was calculated, the activity of SOD, CAT, GSH-PX and the content of MDA in spleen were determined, and the serum content of IL-2, IL-6, IgA, IgG, IgM were evaluated. The results revealed that the spleen index of kinetin treatment groups was significantly or extremely significantly higher than that of aging model control group(P0.05 or P0.01); the activity of the 3 tested antioxidant enzymes of kinetin treatment groups was increased in different degree compared with that of aging model control group, and the high dosage kinetin group exhibited extreme significance(P0.01); the content of MDA in spleen of kinetin treatment groups was significantly or extremely significantly reduced compared with that of aging model control group(P 0.05 or P 0.01); the serum content of IL-2 of kinetin treatment groups was significantly or extremely significantly higher than that of aging model control group(P 0.05 or P 0.01), and the serum content of IL-6 was significantly or extremely significantly lower than that of aging model control group(P0.05 or P0.01); the serum content of the 3 tested globulins of kinetin treatment groups was increased in different degree compared with that of aging model control group,and the high dosage kinetin group exhibited extreme significance(P0.01). Based on the results obtained in this study, it can be concluded that kinetin are capable to delay aging, resist oxidation damage and enhance immunity.

CLC Number: